AEGiS-Reuters: Triangle to start DMP-450 HIV-drug testing in January

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Triangle to start DMP-450 HIV-drug testing in January

Reuters NewMedia, Inc.; Monday December 22, 10:10 am EST

DURHAM, N.C., Dec 22 (Reuters) - Triangle Pharmaceuticals Inc ON Monday said the government removed a clinical hold on testing of its HIV drug, DMP-450, and the company has agreed to start Phase I studies in January.

"We are very pleased that we have been able to rapidly reach agreement with the Food and Drug Administration to reinitiate clinical studies with DMP-450," said David Barry, chairman of the company, in a release.

The company said it obtained worldwide license rights to the drug when it acquired Avid Corp.

DMP-450 is a anti-HIV protease inhibitor.

971222
RE971220

Copyright © 1997 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .